History
Definition:
Leprosy is a chronic systemic
disease caused by Mycobacterium leprae
manifesting as development of specific
granulomatous or neurotrophic lesions in the
skin, mucous membrane, eyes nerves, bones
and viscera.
}
GIT : ingestion of food Not
Yet
Intradermal : inoculation by tattoos Proven
Epidemiological factors
Occurs at all age groups
Peak age of onset : Between 10 20 years
Males > Females
Children most susceptible
Immune status ( host resistance)
Overcrowding
Low socioeconomic status
Immunity and Leprosy
Host resistance Clinical manifestation
Excellent No infection
Good Subclinical infection with
spontaneous regression
Fair Indeterminate, pure neuritic,
tuberculoid
Poor Mid-borderline,
borderline-lepromatous
Very poor Lepromatous
Mycobacterium Leprae
Obligate, intracellular, acid-fast bacillus
Affinity for skin, nerves and muscle tissue
Found in macrophages, histiocytes and
Schwann cells.
Non cultivable
Grown in animal models
Closely resembles M.tuberculosis, but less
acid-fast.
Multiplies in 11-13 days.
Classification
The Ridley Jopling classification
Indeterminate
Tuberculoid
Borderline: borderline-tuberculoid,
mid-borderline,
borderline-lepromatous
Lepromatous
Temperature
Tested with two test tubes one containing hot
water and other cold
Pain
Tested by pin prick
Clinical examination : Motor
Testing of motor power- Done clinically
Sural
Investigations for M. Leprae
Bacteriological examination
Skin smears:
Made by slit and scrape method from the most
active looking edge of skin lesion and stained
with Ziehl-Neelsen method.
Reading of smears:
Bacteriological index- Indicates density of leprosy
bacilli (live & dead) in the smears and ranges
from 0 to 6+
Morphological index- It is the percentage of
presumably living bacilli in relation to total
number of bacilli in the smear
Investigations
Histopathological examination
Nerve biopsy
Sweat function test
Lepromin test
Animal Models: Armadillo, Thymectomised,
irradiated nude mice, Korean chipmunk etc.
MDT-WHO
Paucibacillary leprosy (6 months)
- Cap. Rifampicin (600 mg) monthly, supervised
- Tab. Dapsone (100 mg) daily
Multibacillary leprosy (1 year)
- Cap. Rifampicin (600mg) monthly, supervised
- Cap. Clofazimine (300mg) monthly, supervised
- Tab. Dapsone (100mg) daily
- Cap. Clofazimine (50mg) daily
Blister packets for MDT
Easy to use, handy and of convenient size
Provide complete treatment
Improve clinical attendance
Drugs are better protected against
moisture,heat and accidental damage
Ensures quicker dispensing of the drugs
Can be dispensed by non medical person
Lepra Reactions
Acute episodes or bouts of exacerbations
occurring in course of chronic disease
Sudden increase in activity of existing lesions,
appearance of fresh lesions with or without
constitutional symptoms
Type I reaction - all borderline cases (BT,
BB,BL)
Type II reaction - BL & LL cases
Precipitating factors
Physiological conditions like pregnancy
Drugs: anti-leprosy drugs, iodides
Severe physical or mental stress
Infections
Type I Reaction
Sub-types
- Upgrading (Reversal)
- Downgrading
Type IV hypersensitivity reaction.
Existing lesions worsen/New lesions may appear
Neuritis / Nerve abscesses
Systemic disturbances: Unusual
Type I reaction - complications
Neuritis
Dactylitis, edema of hands & feet, inflammation
of small joints of fingers
Corneal anesthesia, Conjunctivitis
Sudden occurrence of claw hand, foot-drop,
facial palsy
Type II Reaction
Occurs in BL and LL cases
Type III hypersensitivity reaction
Erythema Nodosum Leprosum-crops of painful,
recurrent, erythematous, papulonodular lesions.
Fever and malaise
Iridocyclitis, episcleritis, epididymo-orchitis,
arthritis, neuritis, lymphadenitis
Treatment of Lepra reactions
Principles of treatment
Early initiation of treatment for reaction